CYDY - CytoDyn: Q4 Is Crunch Time
- CytoDyn continues to match leronlimab up against COVID-19. The company recently started two clinical trials in Brazil where the pandemic endures.
- If the Brazilian trials hit their endpoints, CytoDyn could file for EUAs in several countries. I expect these trials to produce better results than the U.S. trials.
- The company is moving leronlimab forward in HIV, oncology, NASH, and COVID-19. It is this potential that keeps me involved in the ticker, but Q4 is crunch time.
- I discuss a couple of downside risks and how I plan to manage my CYDY position as we head into Q4.
For further details see:
CytoDyn: Q4 Is Crunch Time